Moving cellular therapies to the front line for Ph<sup>+</sup> B cell acute lymphoblastic leukemia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40669449.
- Also identified by DOI 10.1016/j.xcrm.2025.102184 and PMC identifier 12281393.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemotherapy-free regimens have gained increasing attention as frontline treatments for B cell acute lymphoblastic leukemia (B-ALL) due to the limitations of chemotherapy. Zhang and colleagues conducted the first trial incorporating CAR-T into Ph<sup>+</sup> B-ALL frontline treatment, demonstrating remarkable efficacy and tolerability.<sup>1</sup>.
Medical subject headings
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Immunotherapy, Adoptive
- Cell- and Tissue-Based Therapy